Eli Lilly is investing $5 billion to construct a brand-new biomanufacturing facility in Goochland County, Virginia. The advanced site will be located inside the West Creek Business Park just west of Richmond.
It marks one of the single largest private capital investments in the history of Virginia. The project will create 650 high-wage jobs for the region. It will also generate roughly 1,800 temporary construction jobs during buildout.
The plant will focus on producing complex, cutting-edge therapies, including cancer treatments and antibody-drug conjugates. State leaders praised the partnership, pointing to Virginia’s strong site-readiness programs and workforce training pipelines. Construction will occur in phases, with site validation expected to run into the early 2030s.
Similar Projects
In another similar biomanufacturing facility in the US Genentech’s Hillsboro Campus has recently broken ground on a $750 million expansion. Both projects highlight a massive wave of capital flowing into U.S. biomanufacturing. While Genentech’s $750 million investment expands its long-standing Oregon footprint to specialize in advanced drug-delivery devices, Eli Lilly’s $5 billion Virginia buildout represents a greenfield project focused on complex active pharmaceutical ingredients and therapies like antibody-drug conjugates. Together, these mega-investments underscore a broader industry-wide push by major pharmaceutical leaders to shore up domestic supply chains, scale precision medicine, and build a high-tech manufacturing workforce fit for the next decade.
October 31, 2025
Eli Lilly & Company has revealed plans to build a $5 billion cutting-edge drug manufacturing facility in the West Creek Business Park in Virginia. This marks Lilly’s first fully integrated facility in the U.S. dedicated to Active Pharmaceutical Ingredients (APIs), with a strong focus on bioconjugate technologies and monoclonal antibody therapies.
Strategic Move to Secure Critical Medicine Supply
The facility is being developed as part of Lilly’s broader commitment to four new U.S. manufacturing sites, drawing from over $50 billion in capital commitments since 2020. With concerns about global supply chain disruptions and proposed tariffs on imported pharmaceutical components, this investment aims to enhance supply reliability for cancer, autoimmune disease, and advanced therapy drugs. In parallel, companies like Gilead Sciences are making strategic moves to bolster domestic R&D, underscoring the sector’s push for resilience and innovation in the U.S. healthcare system.
Scope, Jobs & Economic Uplift
Lilly expects the new plant in Goochland County to generate approximately 1,800 construction jobs and 650 high-skilled permanent positions including scientists, lab technicians, and engineers. The facility will produce both APIs and finished drug products on Lilly’s emerging bioconjugate platform, marking a major expansion into advanced therapies.
The project is forecasted to generate significant local economic activity. Eli Lilly is also expected to partner with local universities and support community educational initiatives.
Why Goochland & What Innovation Looks Like
Lilly selected Goochland County after evaluating hundreds of sites. Key deciding factors included workforce availability in the Greater Richmond area, favorable zoning, reliable utilities, transport infrastructure, and state incentive programs. The project will also make use of advanced manufacturing technologies such as automation and machine-learning systems. Additionally, digital integration to ensure high efficiency and quality.
Eli Lilly to build $5B Goochland facility, Positioning the Facility Within Broader Biopharma Trends
The investment comes at a time of increasing push in the U.S. pharma industry toward domestic production of APIs and drug products. Companies like Lilly are responding to proposed import tariffs, geopolitical pressures, and heightened awareness of supply chain risk. Virginia is becoming a hub for biopharma maturation. The state’s life sciences cluster and regulatory environment make it increasingly attractive for large-scale pharmaceutical projects.
Eli Lilly is undertaking one of the largest pharmaceutical manufacturing expansions in U.S. history, committing more than $50 billion to new and expanded facilities across the country. In 2025, the company announced major investments including a $6.5 billion active pharmaceutical ingredient site at Generation Park in Houston, Texas, and a $5 billion biologics and cancer-therapy facility in Goochland County, Virginia. Lilly also unveiled a $1.2 billion expansion at its Carolina complex in Puerto Rico to boost production of oral medicines. These projects join the company’s $4.5 billion manufacturing campus in Lebanon, Indiana, underscoring Lilly’s strategy to expand U.S.-based production capacity for next-generation medicines and strengthen the domestic pharmaceutical supply chain.
Eli Lilly has unveiled plans for a major expansion of its U.S. operations with a $6.5 billion investment in Texas. The new facility will be dedicated to the large-scale production of active pharmaceutical ingredients, a critical step in the company’s strategy to strengthen domestic manufacturing capacity.
Project Factsheet – Lilly’s Goochland Manufacturing Facility
Developer / Operator: Eli Lilly & Company
Location: West Creek Business Park, Goochland County, Virginia
Investment: $5 billion
Purpose: API & drug product facility for antibody-drug conjugates & monoclonal antibodies
Jobs Created: 1,800 construction and 650 high-skill permanent employees
Strategic Drivers: Supply chain resilience; response to tariff risk; advanced therapies
Technologies in operation AI / machine learning; digital integration
Timeline: Built over next 5 years approximately
Cluster & Incentives: VA state incentives; favorable workforce; utilities; transport access
This facility goes beyond mere expansion. It shows Lilly doubling down on producing critical medicine domestically amid rising global unpredictability. It will advance capacity in bioconjugation and antibody therapies. These technologies are expected to shape cancer and immune-disease treatment in the next decade. Also, the economic ripple effects for Virginia will be substantial, with high-wage jobs and local supply chain growth. Furthermore, there is an expected strengthened community R&D partnerships. For industry watchers, this signals a turning point. Large-scale pharma facility projects are becoming essential national infrastructure, not optional business gambits.
Leave a Reply